SPRB logo

SPRB
Spruce Biosciences Inc

4,975
Mkt Cap
$153.11M
Volume
299.00
52W High
$240.00
52W Low
$4.35
PE Ratio
-1.07
SPRB Fundamentals
Price
$56.82
Prev Close
$56.67
Open
$56.82
50D MA
$60.96
Beta
1.21
Avg. Volume
100,220.79
EPS (Annual)
-$50.83
P/B
1.83
Rev/Employee
$0.00
$18.61
Loading...
Loading...
News
all
press releases
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·2h ago
News Placeholder
More News
News Placeholder
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·9d ago
News Placeholder
Spruce Biosciences (SPRB) Projected to Post Earnings on Tuesday
Spruce Biosciences (NASDAQ:SPRB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat·15d ago
News Placeholder
Craig Hallum Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)
Craig Hallum initiated coverage on Spruce Biosciences in a report on Monday. They set a "buy" rating and a $140.00 price target on the stock...
MarketBeat·16d ago
News Placeholder
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Brokerages
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are covering the company, Marketbeat reports. One...
MarketBeat·22d ago
News Placeholder
Why Is Spruce Biosciences Stock Sinking Tuesday?
Spruce Biosciences (SPRB) shares drop 21% in premarket trading following a $60 million public stock offering priced at $50 per share.read more...
Benzinga·22d ago
News Placeholder
Spruce Biosciences Prices Public Offering To Fund Neuro Therapies
(RTTNews) - Spruce Biosciences Inc. (SPRB) announced that it has priced a public offering expected to raise $60 million in gross proceeds to advance its neurological disorder therapies...
Nasdaq News: Markets·22d ago
News Placeholder
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences, Inc. (Spruce Biosciences) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with...
Business Wire·22d ago
News Placeholder
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences, Inc. (Spruce Biosciences) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with...
Business Wire·23d ago
News Placeholder
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
<
1
2
...
>

Latest SPRB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.